



Nucala in Egypt

The EDA named-patient coordination pathway — indicative 2026

PULMONOLOGY · SEVERE EOSINOPHILIC ASTHMA

The clinical situation

Nucala (mepolizumab) is an FDA-approved anti-IL-5 monoclonal antibody indicated for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, hypereosinophilic syndrome, and chronic rhinosinusitis with nasal polyps. Manufactured by GlaxoSmithKline. Dosed 100 mg subcutaneously every 4 weeks in asthma; requires 2–8°C cold-chain storage.

The pathway, 5 steps

- 1 Consultation & clinical rationale.** Your treating pulmonologist confirms eosinophilic phenotype (blood eosinophil count) and documents the clinical rationale and prior-therapy history.
- 2 Administration site confirmed.** An Egyptian respiratory clinic or tertiary hospital accepts the case for supervised injections.
- 3 EDA named-patient application.** Clinical rationale, patient reference, product details, and cold-chain plan are filed with the Egyptian Drug Authority.
- 4 US-side sourcing & logistics.** Reserve Meds coordinates product through our US-licensed DSCSA-compliant specialty wholesale partner on validated 2–8°C cold-chain.
- 5 Arrival & administration.** The clinic receives the dose under temperature-monitored handling; maintenance doses every 4 weeks.

Indicative economics

Reference US cash-pay range: USD 2,800–3,300 per monthly dose. Cold-chain logistics, EDA documentation, and concierge coordination are incremental. Full transparent quote at intake.

Indicative first-dose timing

7–14 days from a complete EDA application to first-dose delivery, once cohort intake opens. Indicative — not guaranteed.

Reserve Meds's role

Sourcing. US-licensed specialty wholesale partner, DSCSA chain-of-custody. **Documentation.** Regulatory package for your physician and EDA review. **Logistics.** Cold-chain, temperature-monitored shipment coordination. **Concierge case lead.** Named point of contact for family and physician through the full process. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating pulmonologist.

COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST

Join the Nucala × Egypt first-cohort waitlist. *Our concierge reaches out as we open intake.*

reservemed.com/access-guides/nucala-egypt.html



SCAN TO JOIN

Reserve Meds · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.

reservemed.com · hello@reservemed.com · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team